Adv Drug Deliv Rev . Adaptive immune responses to SARS-CoV-2

[tetano]

Adv Drug Deliv Rev


. 2021 Feb 18;S0169-409X(21)00043-0.
doi: 10.1016/j.addr.2021.02.009. Online ahead of print.
Adaptive immune responses to SARS-CoV-2


Donald Forthal ¹



Affiliations

• PMID: 33610693
• DOI: 10.1016/j.addr.2021.02.009

Abstract

This review focuses on adaptive immune responses against SARS-CoV-2, the coronavirus that causes COVID-19. A great deal of work has been accomplished in a very short period of time to describe adaptive immune responses and to ascertain their roles in determining the course of infection. As with other viral infections, SARS-CoV-2 elicits both antibody and T-cell responses. Whereas antibody responses are likely effective in preventing infection and may participate in controlling infection once established, it is less clear whether or not they play a role in pathogenesis. T cells are likely involved in controlling established infection, but a pathogenic role is also possible. Longer term evaluation is necessary to determine the durability of protective immune responses.

Keywords: SARS-CoV-2; T cells; antibody; epitopes; immunity; neutralization.